Bydureon (by-DUR-ee-on), the new long-acting form of Byetta (exenatide) for type 2 diabetes
March 2012
You'll see Bydureon (by-DUR-ee-on), the new long-acting form of Byetta (exenatide) for type 2 diabetes.
Bydureon is injected just once a WEEK...compared to twice a day for Byetta or once a day for Victoza (liraglutide).
It sometimes makes sense to add these glucagon-like peptide-1 (GLP-1) agonists to oral meds to improve glycemic control and help patients lose weight.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote